🔗 Share this article

Given that the US proceeds with unprecedented revisions to its immunization guidelines, an unexpected name has surfaced unexpectedly: Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by questioning coronavirus vaccines in the global health crisis and has zeroed in on alleged deaths after COVID-19 vaccination in her short tenure at the FDA.

Planned Shifts to Pediatric Immunization Program

Agency leaders planned to announce sweeping changes to the pediatric vaccine schedule in December, synchronizing the US with Denmark’s immunization schedule, it is understood – a substantial departure that would place the US at odds with much of the world with little proof for improved outcomes. The announcement has been postponed until the coming year.

In place of the top vaccines chief, Høeg is listed to present at the meeting. She was newly appointed acting director of the FDA’s CDER, the fifth appointee to lead the office this calendar year.

Consolidating Power at the FDA

The acting appointment could signify a closer partnership between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a renewed priority upon reevaluating already-approved vaccines at the FDA.

The new acting director has repeatedly called for ending some childhood immunization guidelines in the US in order to be more similar to the Danish model, a nation with comprehensive healthcare and a population approximately the size of Wisconsin’s.

To date comments, she has kept her attention on vaccines – typically the responsibility of Prasad, director of the FDA’s vaccine center – as opposed to medication approval.

Concerns Over Qualifications

Høeg has no obvious background in medication creation, regulation or leadership, which has been standard for former directors of the CBER. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since March.

“She appears not to have any of the qualifications” for leading the drug-regulation department, said Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in managing a large organization. She is not an expert in industry regulation.”

Previous commissioners of the center would “understand laws and regulations and the research of drug development”, commented a former acting FDA commissioner. “Frankly, she has not acquired the sort of resume that prior appointees who headed CBER have had.”

The drug center has an enormous range of responsibilities at the FDA, she stated.

“Everybody just pays attention on the novel medication approvals, but the generic drug division clears a multitude of generic drugs. There’s a biosimilars division, over-the-counter program and so forth, and all of those need to be supervised,” Woodcock said. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

There is also, a major administrative component to the role, which supervises over 5,000 employees. “It is a massive management job, if you do it right,” she said.

Official Statement and Controversial Policies

Regarding questions about Høeg’s fitness for the role and whether this appointment represents more teamwork among FDA leaders on vaccines, a representative responded that the “concerns are based on inaccurate assumptions”.

“Her experience is consistent with the responsibilities of her position,” the representative explained, noting the time Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the commissioner’s new expedited review system, a controversial rapid medication authorization process that reportedly concerned her former heads. “By what process are these drugs being chosen for this voucher program? Who takes the decisions?” Howard said. “There’s a lot of secrecy occurring at the agency right now.”

Overall, he said, “the Food and Drug Administration seems to be moving towards laxer regulations of pharmaceuticals, except for vaccines.”

Established Past Work on Vaccines

With vaccines, Høeg has a clearer, if troubling, history, Howard observe. She published a study using non-validated volunteer-provided data to determine the frequency of myocarditis following Covid vaccination. She advised the Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccinations are pose a greater threat than they are.

Among her “desired changes” for the current administration encompassed altering guidelines for new vaccines and ending “non-essential” vaccines, she said following the vote on a online show. At the FDA, Dr. Høeg has allegedly proposed excluding teenage boys from obtaining Covid vaccinations.

“She’s an thorough ideologue who starts off with her beliefs and reverse-engineers to retrofit the evidence in a extremely deceptive, dishonest way,” Howard stated.

Gaining Influence and a “Push for Payback”

Høeg joined other dissenters, {like|